AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04455542 — intervention group
Intervention type: OTHER
Intervention: FAS and FLS
Description: The clinical symptoms were confined to upper limbs (FAS) or lower limbs (FLS) for more than 12 months, and the main manifestations were lower motor neuron involvement signs such as muscle weakness and atrophy.
Study NCT00817739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: Leuprorelin injection
Study NCT00817739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: Leuprorelin injection
Study NCT00817739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Flutamide tablets
Study NCT00817739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide tablets
Study NCT00179478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta 1a 30 ug IM once weekly
Description: Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
Study NCT00179478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon beta 1a 30 ug IM once weekly
Description: Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
Study NCT04471298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qishenyiqi dripping pills, 6 bags
Description: 28 consecutive days
Study NCT04471298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qishenyiqi dripping pills, 9 bags
Description: 28 consecutive days
Study NCT04471298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Qishenyiqi dripping pills, 12 bags
Description: 28 consecutive days
Study NCT04471298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishenyiqi dripping pills placebo, 6 bags
Description: 28 consecutive days
Study NCT04471298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishenyiqi dripping pills placebo, 9 bags
Description: 28 consecutive days
Study NCT04471298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishenyiqi dripping pills placebo, 12 bags
Description: 28 consecutive days
Study NCT04550455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine Tablets
Description: Cladribine tablets will be administered according the current package insert guidelines
Study NCT04750772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 68Ga-DOTA-FAPI04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
Study NCT04750772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 18F-DOTA-FAPI04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 18F-DOTA-FAPI04, and undergo PET/CT imaging within the specified time
Study NCT04794439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrices
Description: Dentifrice on plaque
Study NCT05226728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Eligible patients received pembrolizumab 200mg every 3 weeks with or without chemotherapy for four cycles, then for patients without progressive disease, pembrolizumab was administrated in new dose-intervals according to steady state plasma-concentration (Css) of pembrolizumab until disease progression
Study NCT05980078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive consent
Description: They were randomized to complete an interactive consent.
Study NCT05980078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard consent
Description: They were randomized to complete a standard written consent.
Study NCT02607956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Description: 50 mg tablets administered orally, once daily
Study NCT02607956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF
Description: 200/25 mg tablets administered orally, once daily
Study NCT02607956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 milligrams (mg) FDC tablets administered orally, once daily
Study NCT02607956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG Placebo
Description: Tablets administered orally, once daily
Study NCT02607956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF Placebo
Description: Tablets administered orally, once daily
Study NCT02607956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablets administered orally, once daily
Study NCT02354144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carrageenan-based gel
Description: Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
Study NCT02354144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control gel
Description: A gel not containing carrageenan
Study NCT03542604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
Study NCT03542604 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education
Description: EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
Study NCT00001806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Education and Counseling
Description: Group Education and Counseling
Study NCT00001806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Education and Counseling
Description: Individual Education and Counlseing
Study NCT03987815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study NCT03820388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 2mg/kg
Description: 2 mg/kg
Study NCT03820388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg
Description: 0.3 mg/kg
Study NCT01821040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodotra®
Description: Lodotra, starting dose of 15mg administered in the evening
Study NCT03820388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg/kg
Description: 1 mg/kg Propofol
Study NCT03820388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate 0.15 mg/kg
Description: 0.15 mg/kg Etomidate
Study NCT01821040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone IR (immediate release)
Description: Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
Study NCT01745835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L Coolprep®
Description: \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Study NCT01745835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1L Coolprep® and Bisacodyl
Description: 1. Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~   \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~2. Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) \* composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg
Study NCT03710850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
Study NCT00742560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Anti-TNF alpha originator
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Adalimumab
Description: Anti-TNF alpha originator
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Etanercept
Description: Anti-TNF alpha originator
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Golimumab
Description: Anti-TNF alpha originator
Study NCT00742560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Certolizumab Pegol
Description: Anti-TNF alpha originator
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab biosimilar
Description: Anti-TNF alpha Infliximab biosimilars
Study NCT04584593 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sample
Description: Men will give semen, saliva, nasopharyngeal, urine and blood specimens
Study NCT00582777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: USUAL - take your BP Meds as you usually do
Description: The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
Study NCT00582777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HS DOSING
Description: Take your usual BP meds at bed time
Study NCT00582777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADD On Dosing
Description: Take your usual BP meds but add one more med at bed time.
Study NCT02138968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Description: Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
Study NCT00551603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: switch (epoetinum beta, darbepoetinum)
Description: switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
Study NCT00551603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuation (darbepoetinum)
Description: continuation of the previous darbepoetinum administration schedule
Study NCT02860715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is the placebo of GX-I7 described above.
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Etanercept biosimilar
Description: Anti-TNF alpha Etanercept biosimilar
Study NCT03016260 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab biosimilar
Description: Anti-TNF alpha Infliximab biosimilar
Study NCT03279731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Description: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
Study NCT03279731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
Study NCT00742560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone oral
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
Study NCT00742560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
Study NCT04153500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomy class with Pelvic+ methodology
Description: Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
Study NCT01455012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
Study NCT01455012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
Study NCT00735878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-751 and Carboplatin
Description: This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
Study NCT01059370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bowel emptying
Description: Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
Study NCT03320564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F-18 FDG PET
Description: Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
Study NCT03320772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMVP1-ICG
Description: Detection of SLN
Study NCT03320772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICG
Description: Detection of SLN
Study NCT02283515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
Study NCT01121692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Intervention
Description: The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
Study NCT01121692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's CoOp
Description: The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
Study NCT01121692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women's CoOp and Men's Intervention
Description: The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
Study NCT04681482 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation.
Study NCT03608774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
Study NCT03608774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
Study NCT03608774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
Study NCT03125434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EOS full-spine, MRI, gait analysis
Description: full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
Study NCT02609334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRD007
Description: One single dose given 3 hours prior to Mannitol challenge
Study NCT02609334 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose given 3 hours prior to Mannitol challenge
Study NCT03766854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
Study NCT03766854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U100
Description: Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
Study NCT04305795 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 200 mg Pembrolizumab
Description: every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
Study NCT04305795 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 350 mg Cemiplimab
Description: every 3 weeks on Days 1 and 22 of each 6-week cycle for up to 24 months.
Study NCT04305795 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ASP-1929
Description: ASP-1929 IV on Day 8 of each 6-week cycle for up to 24 months.~Photoimmunotherapy Light Treatment on Day 9 of each 6-week cycle for up to 24 months.
Study NCT00699556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 21mg transdermal nicotine patch (Nicoderm CQ)
Description: 21mg transdermal nicotine patch
Study NCT00699556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21mg transdermal nicotine patch (Nicoderm CQ)
Description: 21mg transdermal nicotine patch
Study NCT00699556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg nicotine nasal spray
Description: two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
Study NCT00699556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
Study NCT03022292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Ophthalmic
Description: IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC